secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152292
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab plus chemo gets NMPA approval in China for EGFRm NSCLC; PFS HR 0.46 in HARMONi-A
--------------------------------------------------------------------------------

- NMPA approved ivonescimab + chemo for 2L+ EGFR-mutant non-squamous NSCLC based on HARMONi-A Phase III trial sponsored by Akeso.
- PFS hazard ratio 0.46 (p<0.001); median PFS 7.1 months vs 4.8 months for placebo + chemo.
- ORR 50.6% vs 35.4% and DCR 93.1% vs 83.2%; OS trended positive (HR 0.72 at 10.2 mo follow-up).
- Subgroup with 3rd-gen TKI: PFS HR 0.48; safety manageable — 5.6% discontinued ivonescimab due to TRAEs.
- Multi-regional HARMONi trial (target 420 patients) enrolling; completion expected in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524152292/0001193125-24-152292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524152292/d38200d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer